On October 18, 2024, at the 19th Annual Cardiometabolic Health Congress (CMHC), a poster titled “Utilization of High-Sensitivity C-Reactive Protein Testing in Primary and Secondary ASCVD Prevention” was presented by authors Emil deGoma, MD, Yung Chyung, MD, John Walsh, MD, C. William Pike, MD, Jananee Muralidharan, MD, Vincent Marino, J. Craig Davis, Saurabh Gombar MD, PhD, and Michael D. Shapiro, DO, MCR. The authors are affiliated with Tourmaline Bio, Inc. Atropos Health, Inc., and Wake Forest University School of Medicine.

Key Conclusions:

  • The real-world evidence analysis found low rates of hs-CRP testing in both primary and secondary prevention settings in the US. This highlights the need for increased awareness and clinical translational efforts to improve hs-CRP testing.

About Tourmaline Bio
Tourmaline is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune and inflammatory diseases.

See the poster here: Hs_CRP_CMHC_Poster_FINAL_08OCT2024

Read the press release here: https://ir.tourmalinebio.com/news-releases/news-release-details/tourmaline-bio-showcase-two-poster-presentations-2024

To learn how Atropos Health can accelerate and supplement your research with Real-World Evidence (RWE), email us: sales@atroposhealth.com